Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Agios Pharmaceuticals Inc shares valued at $8,768 were sold by Scadden David on Nov 12 ’25. At $43.84 per share, Scadden David sold 200 shares. The insider’s holdings dropped to 17,603 shares worth approximately $0.39 million following the completion of this transaction.
Also, Gheuens Sarah sold 2,454 shares, netting a total of over 107,436 in proceeds. Following the sale of shares at $43.78 each, the insider now holds 61,727 shares.
Before that, SARAH GHEUENS had added 2,454 shares to its account. In a trade valued at $107,441, the Officer bought Agios Pharmaceuticals Inc shares for $43.78 each.
As published in a research note from RBC Capital Mkts on November 19, 2025, Agios Pharmaceuticals Inc [AGIO] has been rated down from an Outperform to a Sector perform and the price target has been revised to $28. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in late February. As of October 16, 2024, Scotiabank has initiated its “Sector outperform” rating for AGIO.
Analyzing AGIO Stock Performance
On last trading session, Agios Pharmaceuticals Inc [NASDAQ: AGIO] plunged -50.89% to $22.34. The stock’s lowest price that day was $22.24, but it reached a high of $25.0699 in the same session. During the last five days, there has been a drop of approximately -48.80%. Over the course of the year, Agios Pharmaceuticals Inc shares have dropped approximately -58.46%. Shares of the company reached a 52-week high of $46.00 on 11/18/25 and a 52-week low of $22.24 on 11/19/25.
Support And Resistance Levels for Agios Pharmaceuticals Inc (AGIO)
According to the 24-hour chart, there is a support level at 21.36, which, if violated, would cause prices to drop to 20.39. In the upper region, resistance lies at 24.19. The next price resistance is at 26.05. RSI (Relative Strength Index) is 21.21 on the 14-day chart, showing oversold technical sentiment.
Is Agios Pharmaceuticals Inc subject to short interest?
Stocks of Agios Pharmaceuticals Inc saw a sharp steep in short interest on 2025-10-31 dropping by -0.58 million shares to 4.6 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 5.18 million shares. A decline of -12.57% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.31 of the overall float, the days-to-cover ratio (short ratio) decline to 8.31.
Which companies own the most shares of Agios Pharmaceuticals Inc (AGIO)?
In terms of Agios Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 56 in the next 12 months, up nearly 23.1% from the previous closing price of $45.49. Analysts anticipate Agios Pharmaceuticals Inc stock to reach 56 by 2025, with the lowest price target being 56. In spite of this, 5 analysts ranked Agios Pharmaceuticals Inc stock as Buy at the end of 2025. On September 27, 2024, Leerink Partners assigned a price target of “a Market perform” to the stock and downgraded coverage with a $56.
